Results 261 to 270 of about 171,342 (310)

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

Advanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang, Shengxin Lu, Guangyong Zheng, Shensuo Li, Hongyu Chen, Mei Hong, Xiangru Zhou, Ruotian Tang, Ye Wu, Weidong Zhang, Dong Lu, Xin Luan   +11 more
wiley   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Advanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao   +7 more
wiley   +1 more source

Knockout of Mucin 1 inhibits the proliferation, migration, and invasion of human MDA-MB-231 cells by blocking autophagy flow. [PDF]

Braz J Med Biol Res
Huang Z, Zhao J, Zhang Q, Luo Y, Chen W, Liu Z, Liu X.   +6 more
europepmc   +1 more source

ZDHHC17‐Mediated CDK4 Palmitoylation Drives Cell Cycle Progression and Orchestrates Cancer Immune Surveillance

Advanced Science, EarlyView.
ZDHHC17 palmitoylates CDK4, which together with TRAF6‐mediated ubiquitination, drives cell cycle progression and immune surveillance, revealing a rational combination of CDK4 inhibitors with immune checkpoint blockers for ZDHHC17‐driven cancers. ABSTRACT Uncontrolled cell cycle progression is a hallmark of cancer, tightly regulated by both intrinsic ...
Zekang Wang, Peipei Song, Xueji Wu, Lei Wang, Wei Xie, Pinning Feng, Chao Cheng, Jianping Guo   +7 more
wiley   +1 more source

The LNK adaptor protein: a dual regulator of proliferation and migration in solid tumors. [PDF]

Mol Cell Oncol
Mantilla-Ollarves JC, Velazquez L, Rocha-Zavaleta L.   +2 more
europepmc   +1 more source

Genomic landscape, immune microenvironment and survival in male versus female breast cancer. [PDF]

ESMO Open
Trapani D, Deshmukh SK, Samec T, Wu S, Xiu J, Walker P, Abravanel DL, Advani P, Spanheimer PM, Lin NU, Curigliano G, Graff SL, Lustberg M, Sledge GW, Tolaney SM, Leone JP.   +15 more
europepmc   +1 more source

Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer. [PDF]

Int J Mol Sci
Masisi BK, El Ansari R, Fakroun A, Erkan B, Rakha EA, Green AR.   +5 more
europepmc   +1 more source

Upregulation of Caveolin-1 in breast cancer and its potential value in distinguishing TNBC from non-TNBC: an immunohistochemical study. [PDF]

Front Oncol
Wang CQ, Shao JK, Wang Y, Lu SP, Xu ZG, Hu CH, Huang BF.   +6 more
europepmc   +1 more source

Prognostic Significance of the CRP-Albumin-Lymphocyte Index (CALLY) in Triple Negative Breast Cancer Patients: A Real-World Retrospective Study. [PDF]

Breast Cancer (Dove Med Press)
Liu Y, Zhang F, Guo C, Li Q.
europepmc   +1 more source

Alterations in PD-L1⁺ Myeloid Cells and Immune Infiltration Are Associated with Atezolizumab and Paclitaxel Therapy Success in a Triple-Negative Breast Cancer Model. [PDF]

Medicina (Kaunas)
Yilmaz KB, Tavukcuoglu E, Yanik H, Seçken P, Celik E, Guler S, Hidiroglu MM, Bahcecioglu IB, Erturk I, Gulcelik MA, Karakoc D, Esendagli G.   +11 more
europepmc   +1 more source